Video Gallery

We achieved encouraging results, knowledge and experience in vaccine development from our prior research collaboration with Sanofi Pasteur (which is anticipated to end in October 2016) that we believe can be leveraged and built upon with other partners. During the collaboration, meaningful improvements were made to the C1 expression system to produce antigens of interest that Sanofi further tested in mice trials. The mice trial data indicated that the C1 produced antigen generated an equal or better immune response in mice than the industry standard antigen.

Dyadic CEO & CCO Interviewed by OTC Markets Group, February 2018
Dyadic International, Inc. (OTCQX: DYAI) Inv€$table Showcase Biotech and Money November 2017
Dyadic International, Inc. (OTCQX: DYAI) Virtual Investor Conference October 2017
Dyadic International, Inc. (OTCQX: DYAI) The Innovation Show – August 2017 | From Stonewashed Jeans to Lifesaving Genes
Dyadic Seeks to Bring Disruptive Technology to Biomanufacturing, The Bio Report, June 2017
Update with Dyadic International, Inc. (OTCQX: DYAI) - October 2016 | Stock News Now
Dyadic International, Inc. (OTCQX: DYAI): Managing Director, Biz Dev/Licensing | Stock News Now
Dyadic International, Inc. (OTCQX: DYAI) with CSO - October 2016 | Stock News Now
SCN’s Wendy Gillette Interview of Dyadic Intl (DYAI) CEO Mark Emalfarb Conducted at the NASDAQ MarketSite Informative on
July 26, 2016
Dyadic’s CEO Mark Emalfarb Interview with Stock News Now,
June 2016
Dyadic’s CEO Mark Emalfarb, Details Company’s Inflection Point May 6, 2016 – NYC, PIONEERS 2016, Joseph Gunnar & Co.